Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42869   clinical trials with a EudraCT protocol, of which   7063   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2014-003509-13
    Sponsor's Protocol Code Number:MLN0002-3028
    National Competent Authority:Czechia - SUKL
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2015-04-27
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedCzechia - SUKL
    A.2EudraCT number2014-003509-13
    A.3Full title of the trial
    An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Active Crohn's Disease Treated With Vedolizumab IV
    Otevřené klinické hodnocení fáze 3b posuzující slizniční hojení u pacientů
    se středně závažnou až závažnou aktivní Crohnovou chorobou léčených
    vedolizumabem IV
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Effect of Vedolizumab IV in subjects with Crohn's Disease
    A.3.2Name or abbreviated title of the trial where available
    Effect of Vedolizumab IV on Mucosal Healing in Crohn's Disease
    A.4.1Sponsor's protocol code numberMLN0002-3028
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorTakeda Development Centre Europe Ltd
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportTakeda Development Centre Europe Ltd
    B.4.2CountryUnited Kingdom
    B.4.1Name of organisation providing supportTakeda Development Center Americas, Inc
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationTakeda Development Centre Europe Ltd
    B.5.2Functional name of contact pointStudy Manager
    B.5.3 Address:
    B.5.3.1Street Address61 Aldwych
    B.5.3.2Town/ cityLondon
    B.5.3.3Post codeWC2B 4AE
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number442031168000
    B.5.5Fax number442031168199
    B.5.6E-mailclinicaloperations@tgrd.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Vedolizumab IV (Entyvio™)
    D.2.1.1.2Name of the Marketing Authorisation holderTakeda Pharma A/S
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameVedolizumab IV
    D.3.2Product code MLN0002
    D.3.4Pharmaceutical form Powder for concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNVedolizumab
    D.3.9.1CAS number 943609-66-3
    D.3.9.3Other descriptive nameVEDOLIZUMAB
    D.3.9.4EV Substance CodeSUB30452
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number300
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Crohn's Disease
    E.1.1.1Medical condition in easily understood language
    Inflammatory conditions of the large and small intestine
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10011401
    E.1.2Term Crohn's disease
    E.1.2System Organ Class 10017947 - Gastrointestinal disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate endoscopic remission at Week 26 as assessed by ileocolonoscopy.
    E.2.2Secondary objectives of the trial
     Part A
    • To examine the relationship among endoscopic, imaging, histological, and clinical assessments of CD.
    • To evaluate endoscopic remission at Week 14.
    • To evaluate endoscopic response at Weeks 14 and 26.
    • To evaluate clinical response assessed by Crohn’s Disease Activity Index (CDAI) at Weeks 10 and 26.
    • To evaluate clinical remission assessed by CDAI at Weeks 10 and 26.
    Part B
    • To examine the relationship among endoscopic, imaging, histological, and clinical assessments of CD.
    • To evaluate endoscopic remission at Week 52.
    • To evaluate endoscopic response at Week 52.
    • To evaluate clinical response assessed by Crohn’s Disease Activity Index (CDAI) at Week 52.
    • To evaluate clinical remission assessed by CDAI at Weeks 52
    • To evaluate durable endoscopic remission at Week 52 in subjects with endoscopic remission at Week 26.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    An MREn substudy will be conducted at selected qualified centers using a standardized MR acquisition and procedure to assess bowel wall activity. Only subjects from the pre-selected sites will be included in this study; these subjects will undergo an MREn assessment at the Screening and Week 26 or ET visit, unless they have contraindications to the procedure. All MREn results will be evaluated by independent central review.
    The MREn will be conducted at selected sites qualified to perform MREn as assessed by the imaging core lab designated by the sponsor. A standardized MREn acquisition protocol will be implemented across sites and detailed in an Imaging Manual. eGFR to be assessed prior to MREn being performed. MREn will be performed prior to ileocolonoscopy. De-identified MREn images will be transmitted to the imaging core lab where they will be independently analyzed by expert reviewers. Variables evaluated may include, but are not limited to, wall thickness, enhancement of bowel wall after contrast, mural edema, ulcerations, and perienteric vascularity. Bowel assessments will be made in a segmental manner to allow for direct comparison with ileocolonoscopy assessments (terminal ileum plus ascending, transverse, descending and sigmoid colon, and rectum). More proximal small bowel may also be assessed for abnormalities on MREn
    only. One or more of these (including MaRIA) will be used to assess therapeutic response and will be compared to endoscopic response (SES-CD) and clinical response (CDAI) scores.
    E.3Principal inclusion criteria
    - The subject has a diagnosis of moderately to severely active CD at least 3 months prior to enrollment, with a CDAI score of 220-450 during the Screening Period, a SES-CD score of ≥7 and presence of at least one mucosal ulceration documented by recorded ileocolonoscopy at Screening assessed by the central reader.
    - The subject has CD with involvement of the ileum and/or colon that can be assessed by ileocolonoscopy.
    - The subject has demonstrated an inadequate response to, loss of response to, or intolerance of at least 1 of the following agents as defined below:
     Immunomodulators:
    i. The subject has signs and symptoms of persistently active disease despite a history of at least one 12-week regimen of oral azathioprine (≥1.5 mg/kg) or
    6-mercaptopurine (≥0.75 mg/kg), OR
    ii. The subject has a history of intolerance (including but not limited to nausea/ vomiting, abdominal pain, pancreatitis, liver function test abnormalities, lymphopenia, thiopurine S-methyltransferase non wild type [where wild type is
    defined as TPMT*1/*1], infection) to at least 1 immunomodulator.
     TNF- antagonists:
    i. The subject has signs and symptoms of persistently active disease despite a history of at least 1 induction with:
    a) Infliximab: 4-week regimen of 5 mg/kg, 2 doses at 2 weeks apart, OR
    b) Adalimumab: 2-week regimen of 160 mg on Day 1 and 80 mg on Day 15, OR
    c) Certolizumab: 4-week regimen of 400 mg initially at Weeks 0, 2, 4 OR
    ii. The subject has recurrence of symptoms during maintenance dosing following
    prior clinical benefit (discontinuation despite clinical benefit does not qualify), OR
    iii. The subject has a history of intolerance of infliximab, adalimumab, or
    certolizumab, including but not limited to, infusion-related reaction,
    demyelination, congestive heart failure, or infection.
     Corticosteroids
    i. Signs and symptoms of persistently active disease despite a history of at least one
    4-week induction regimen that included a dose equivalent to prednisone 30 mg
    daily orally for 2 weeks or IV for 1 week, OR
    ii. Signs and symptoms of persistently active disease despite treatment with
    budesonide 9 mg daily or 6 mg daily for maintenance, OR
    iii. At least one failed attempt to taper corticosteroids to below a dose equivalent to prednisone 10 mg daily orally, OR
    iv. History of intolerance to corticosteroids (including, but not limited to, Cushing’s
    syndrome, osteopenia/osteoporosis, hyperglycemia, insomnia, and infection).
    E.4Principal exclusion criteria
    - The subject has active or latent tuberculosis, regardless of treatment history, as evidenced by any of the following:
    a) History of TB.
    b) A diagnostic TB test performed during screening that is positive, as defined by:
    i. A positive QuantiFERON® test or 2 successive indeterminate QuantiFERON tests OR
    ii. A tuberculin skin test reaction ≥10 mm (≥5 mm in patients receiving the equivalent of >15 mg/day prednisone)
    - The subject has chronic hepatitis B (HBV) or hepatitis C (HCV) infection.
    - The subject has any identified congenital or acquired immunodeficiency (eg, common variable immunodeficiency, human immunodeficiency virus [HIV] infection, organ transplantation).
    - The subject has evidence of active C. difficile infection or is having treatment for C. difficile infection or other intestinal pathogens during Screening.
    - The subject has evidence of an active infection during Screening.
    - The subject has received any investigational compound within 60 days of enrollment.
    - The subject has received any biologics within 60 days of enrollment.
    - The subject has received any live vaccinations within 30 days prior to enrollment.
    - The subject has a positive PML subjective symptom checklist during screening and prior to the administration of study drug on Day 1.
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint is the proportion of subjects achieving endoscopic remission, defined as a simple endoscopic score for Crohn’s Disease (SES-CD) score of ≤ 4 at Week 26.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 26
    E.5.2Secondary end point(s)
    -The secondary endpoints for this studyPart A are:
    • Proportion of subjects achieving complete mucosal healing (defined as absence of ulceration) at Week 26.
    • Proportion of subjects achieving endoscopic remission at Week 14.
    • Proportion of subjects with endoscopic response (defined as SES-CD reduction by ≥50%) at Week 14.
    • Proportion of subjects with endoscopic response (defined as SES-CD reduction by ≥50%) at Week 26.
    • Proportion of subjects achieving clinical response (CDAI decrease from Baseline of ≥100 points) at Week 10.
    • Proportion of subjects achieving clinical response (CDAI decrease from Baseline of ≥100 points) at Week 26.
    • Proportion of subjects achieving clinical remission (CDAI ≤150) at Week 10.
    • Proportion of subjects achieving clinical remission (CDAI ≤150) at Week 26.

    The secondary endpoints for Part B are:
    • Proportion of subjects achieving complete mucosal healing (defined as absence of ulceration) at Week 52.
    • Proportion of subjects achieving endoscopic remission at Week 52.
    • Proportion of subjects with endoscopic response (defined as SES-CD reduction by ≥50%) at Week 52.
    • Proportion of subjects achieving clinical response (CDAI decrease from Baseline of ≥100 points) at Week 52.
    • Proportion of subjects achieving clinical remission (CDAI ≤150) at Week 52.
    • Proportion of subjects with durable clinical remission, defined as clinical remission at Week 26 and Week 52.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Week 10, 14 , 26 and 52
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA43
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    EoT will be the date of last visit of last subject at Postdose 18 week
    Safety Follow-up visit.
    Subjects who consent to Part B will have option to voluntarily enroll into an XAP study after Final Visit or Week 52 in MLN0002-3028. Subjects who transition into XAP study will not take part in 18-week follow-up period or the 6-month safety follow-up call following their last dose in MLN0002-3028. EoT will be the Week 52 visit for these subjects and duration of study will be approximately 56 weeks.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years2
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 100
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 10
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception Information not present in EudraCT
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others Information not present in EudraCT
    F.4 Planned number of subjects to be included
    F.4.1In the member state21
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 58
    F.4.2.2In the whole clinical trial 100
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The study medication will not be available upon completion of the
    subject's participation in the study. The subject should be returned to
    the care of a physician and standard therapies as required.
    Subjects will have the option to transition to the XAP study provided
    that:
    *Vedolizumab is not available through commercial channels
    *The subject will continue to derive benefit from vedolizumab and
    continued treatment is desired
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-06-25
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-05-06
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2018-02-21
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA